Well spotted @hottod ! It appears that PYC has gone stealthy even in filing their patents. They used to mention specific areas like:
Kidney Diseases 1, 2, 3
Glaucoma
Optic Atrophy
Now, their patents are getting so broad that they could cover many different diseases. Here is a list of their stealthy patents:
Modulating Inflammation 1, 2, 3
Alzheimer's disease
Asthma
Cancer
Heart disease
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS)
Type 2 diabetes
Modulating Autophagy
Strengthening the immune system to prevent diseases
Encephalopathy (disease of the brain that alters brain function or structure. It might be caused by infectious agent such as bacteria, virus, or prion)
Alzheimer’s disease
Age-related cataracts
Monogenic Neurodevelopmental Disorders 1, 2, 3, 4
Autism and other neurodevelopmental disorders below
Rett syndrome
Fragile X syndrome
Angelman syndrome
Prader-Willi syndrome
The SP right now does not reflect the true value of the company, Let's look at it as a coiled spring, the longer the big pharmas are sitting on their hands and not investing into PYC, the harder the spring is coiled. When one decided to team up, the rest would rush in like a flock in a feeding frenzy, bashing down their door with higher bids.
I know it's a long road from research to human trials to commercial sales. But judging on the breath and depth of their patent filing, the future is very bright indeed.
From a medical point of view, their RNA focus is on fundamental issues with the human body such as inflammation and autophagy. If they could successfully bring these processes under control through modulation, the benefit would be enormous and you would be looking at a market cap of > US$100b*, i.e. 800X of current SP or > A$50 per share.
* Note: A very conservative estimate of annual earnings = US$10b and P/E ratio = 10x => Market cap of US$100b. DYOR !
Please click the Great Analysis button if you appreciate my thoughts
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)